Skip to main content
DTIL
NASDAQ Life Sciences

Precision BioSciences Details HBV Trial Data, Initiates DMD Clinical Trial

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$7.94
Mkt Cap
$202.806M
52W Low
$3.53
52W High
$8.82
52W Position info
125% above low
Off High info
10.0% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

DTIL has more than doubled off its 52-week low of $3.53.

Summary

Precision BioSciences provided detailed positive clinical data for its chronic hepatitis B program and initiated a new clinical trial for Duchenne muscular dystrophy.


Key Events · Product Development and Regulatory · DTIL

  • Detailed HBV Clinical Data

    Liver biopsy data from the ELIMINATE-B study showed PBGENE-HBV directly eliminated cccDNA, leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts, reinforcing the mechanism of action.

  • DMD Clinical Trial Commenced

    The FUNCTION-DMD clinical trial for Duchenne muscular dystrophy has commenced with the activation of a second clinical site, targeting initial safety data by year-end 2026.

  • Next Program Updates

    The company is targeting year-end 2026 for the next program updates for both the PBGENE-HBV and FUNCTION-DMD clinical trials.


Analysis · DTIL · Life Sciences

This filing provides crucial scientific validation for Precision BioSciences' lead gene editing program, PBGENE-HBV, by detailing liver biopsy data showing direct cccDNA elimination and a 1-log reduction in transcripts. Simultaneously, the company has commenced its FUNCTION-DMD clinical trial for Duchenne muscular dystrophy, expanding its clinical pipeline and targeting initial safety data by year-end 2026. These updates reinforce the company's clinical progress and pipeline development.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, DTIL was trading at $7.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $202.8M. The 52-week trading range was $3.53 to $8.82. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DTIL - Latest Insights

DTIL
Nov 05, 2026, 7:10 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $7.73
Real-time Price: $7.57 info
Change: -$0.165 (-2%) info
Market Cap: $211.334M info
DTIL
Nov 05, 2026, 7:07 AM EST
Filing Type: FWP
Importance Score:
7
Price at Filing: $8.50
Real-time Price: $7.57 info
Change: -$0.935 (-11%) info
Market Cap: $211.334M info
DTIL
Nov 05, 2026, 7:01 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.39
Real-time Price: $7.57 info
Change: -$0.825 (-10%) info
Market Cap: $211.334M info
DTIL
Nov 05, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $8.57
Real-time Price: $7.57 info
Change: -$1.01 (-12%) info
Market Cap: $211.334M info
DTIL
Nov 05, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $8.39
Real-time Price: $7.57 info
Change: -$0.825 (-10%) info
Market Cap: $211.334M info